(Circulation. 1995;91:417-425.)
© 1995 American Heart Association, Inc.
Articles |
Photodynamic Therapy of Normal and Balloon-Injured Rat Carotid Arteries Using 5-Amino-Levulinic Acid
From the Department of Surgery (I.N., A.M., S.B.), National Medical Laser Centre, University College London Medical School, The Rayne Institute; the Division of Cardiology (S.A., J.M.), Hatter Institute for Cardiovascular Studies, University College London Hospitals; and UCL Hospitals Vascular Unit (I.N., C.B.), The Middlesex Hospital, Mortimer Street, London, UK.
Correspondence to Isaac Nyamekye, MBChB, FRCS, Department of Surgery, National Medical Laser Centre, University College London Medical School, The Rayne Institute, 5 University St, London WC1E 6JJ, UK.
Background Although the management of atherosclerotic disease by the use of balloon angioplasty is widespread, the treatment is limited by restenosis in 30% to 50% of cases. Fibrocellular intimal hyperplasia, the main cause of restenosis, arises from proliferation and migration of medial smooth muscle cells (SMC) into the intimal layer. Factors leading to intimal hyperplasia are incompletely understood, and drugs have universally failed to influence clinical restenosis. Photodynamic therapy (PDT), the light activation of photosensitizing drugs to generate cytotoxic mediators, may have potential as prophylaxis for intimal hyperplasia. 5-Amino-levulinic acid–induced protoporphyrin IX (ALA-PPIX), a naturally occurring porphyrin precursor, and its product, -PPIX, offers a novel method of sensitization for PDT. We have investigated the pharmacokinetics of ALA in arteries and the effects of ALA-PPIX–sensitized PDT on normal and balloon-injured arteries.
Methods and Results ALA (20 to 200 mg/kg) was injected into healthy rats, and PPIX fluorescence was measured in the carotid arteries. In a second group of rats, the exposed carotid artery was laser illuminated (50 J/cm2, 630 nm) 30 to 90 minutes after sensitization. Three and 14 days after PDT, histological sections from treated arteries were analyzed by light microscopy. Subsequently, two new groups of rats underwent PDT (ALA, 100 mg/kg; laser, 50 J/cm2, 630 nm [at 60 to 90 minutes]). The left carotid arteries underwent balloon angioplasty by intraluminal passage of a Fogarty FG2 catheter immediately before irradiation. These rats were killed at 14 and 28 days together with laser-only, ALA-only, and untreated control rats. The arteries were perfusion-fixed in vivo. ALA-PPIX induced arterial media fluorescence in a dose-dependent manner. In the normal arteries, PDT produced a dose-dependent cellular depletion in the treated arterial segment at 3 days, and this was complete with 100 and 200 mg/kg of ALA. At 14 days, the media remained acellular, although the endothelial lining had regenerated. In the balloon-injured arteries, PDT produced complete inhibition of intimal hyperplasia at both 14 and 28 days (0%). This was significantly greater than that produced by any of the control rats (34% to 69% and 37% to 66% at the two times, respectively). Significance was at 99% using ANOVA and Fisher's PLSD test. No hemorrhage, thrombosis, or aneurysm formation was seen.
Conclusions ALA-PPIX–sensitized PDT applied at the time of angioplasty effectively inhibits experimental intimal hyperplasia development in rats. This may offer a new approach to the management of angioplasty restenosis in patients.
Key Words: photodynamic therapy • angioplasty • stenoses
This article has been cited by other articles:
 |
|
 |
|
  C. J. Mingone, S. A. Gupte, J. L. Chow, M. Ahmad, N. G. Abraham, and M. S. Wolin Protoporphyrin IX generation from {delta}-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate cyclase activation. Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L337 - L344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Mansfield, S Bown, and J McEwan Photodynamic therapy: shedding light on restenosis Heart, December 1, 2001; 86(6): 612 - 618. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Rockson, D. P. Lorenz, W.-F. Cheong, and K. W. Woodburn Photoangioplasty : An Emerging Clinical Cardiovascular Role for Photodynamic Therapy Circulation, August 1, 2000; 102(5): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P Jenkins, G. A Buonaccorsi, R. Mansfield, C. C.R Bishop, S. G Bown, and J. R McEwan Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid Cardiovasc Res, January 14, 2000; 45(2): 478 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heckenkamp, D. Leszczynski, J. Schiereck, J. Kung, and G. M. LaMuraglia Different Effects of Photodynamic Therapy and {gamma}-Irradiation on Vascular Smooth Muscle Cells and Matrix : Implications for Inhibiting Restenosis Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2154 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. de Vries, A. C. E. Moor, T. M.A.R. Dubbelman, T. J. C. van Berkel, and J. Kuiper Oxidized Low-Density Lipoprotein as a Delivery System for Photosensitizers: Implications for Photodynamic Therapy of Atherosclerosis J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 528 - 534. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Heckenkamp and G. M. Lamuraglia Intimal Hyperplasia, Arterial Remodeling, and Restenosis: An Overview Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1999; 11(2): 71 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G Bown Science, medicine, and the future: New techniques in laser therapy BMJ, March 7, 1998; 316(7133): 754 - 757. [Full Text]
|
|
|
|
|
|
R. G Statius van Eps, F. Adili, and G. M LaMuraglia Photodynamic therapy inactivates cell-associated basic fibroblast growth factor: a silent way of vascular smooth muscle cell eradication Cardiovasc Res, August 1, 1997; 35(2): 334 - 340. [Abstract] [Full Text] [PDF]
|
|